Cadrenal Therapeutics, Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
3.10M
on 2026-06-30, from 1.07M on 2024-03-31 10-Q ↗
Earlier counts are adjusted for the 1-for-15 reverse split; each bar's tip shows the count as filed.
a raise that quarter, at its price
Newest
S-3 of 2024-11-14. Not read yet. S-3 ↗
$3.4M
H.C. Wainwright, agreement of 2025-11-18. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗
Warrants
The 10-Q filed 2026-08-13 is not read yet.
Cash
0.9 quarters
$2.4M on 2026-06-30 ÷ $2.5M a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2026-06-30 | Private placement incl. 0.96M pre-funded | 1,920,000 | not read | $3.0M | 8-K ↗ |
| 2026-04-01 | Public offering | 590,001 | not read | not read | 424B5 ↗ |
| 2026-03-31 | Private placement | 571,430 | not read | $2.5M | 8-K ↗ |
| 2025-12-23 | Public offering | not read | $14.1345 | not read | 424B5 ↗ |
| 2025-12-15 | Public offering | not read | not read | not read | 424B5 ↗ |
| 2025-12-15 | Registered direct offering | not read | $14.1345 | $2.3M | 424B5 ↗ |
| 2025-12-15 | Registered direct offering | 414,748 | not read | $2.2M | 8-K ↗ |